Location:Home > Xiangya News > News

Team of Associate Prof. Huang Qiong Publishes Review in International Top Journal Nano today


Recently, the team of Associate Professor Huang Qiong from Department of Pharmacy of Xiangya Hospital, Central South University, and the team of Prof. Ai Kelong from Xiangya School of Pharmaceutical Sciences, Central South University, published a review titled “Rheumatoid arthritis microenvironment insights into treatment effect of nanomaterials” in international top journal Nano today (IF=20.722, Q1). Prof. Ai Kelong and Associate Professor Huang Qiong are co-corresponding authors. Post-graduate students Zhu Yan and Zhao Tianjiao are co-first authors. Xiangya Hospital of Central South University is the first affiliation and the corresponding affiliation.

Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that causes a huge medical burden due to its high morbidity and disability rate. At present, clinically used RA medication is mainly for anti-inflammatory purposes and the efficacy of most drugs is no longer satisfactory. Uncontrolled RA progression cannot be explained by high levels of inflammation alone, as rheumatoid arthritis microenvironment (RAM) has a great influence on the biological behavior of RA, such as synovial hyperplasia, angiogenesis, cartilage, and bone destruction. RAM is an extremely complex network system formed by the crosstalk of various extracellular matrix factors and a variety of stromal cells. It has tumor-like enhanced permeability retention (EPR), which not only provides appropriate materials and energy for the occurrence and development of RA, but also provides a huge opportunity for efficient RA targeted treatment.

Traditional medication has low treatment efficacy and increased side effects due to difficulty in simultaneous interference with multiple factors and weak interactions with targets. Nanomaterials, however, can effectively capture and interfere with various pathogenic factors in RAM by changing their structural composition, surface functionalization, and drug loading efficiency. More importantly, nanomaterials can significantly improve treatment efficacy and reduce side effects through EPR passive targeting and RAM responsive active targeting strategies. The inherent advantages of nanomaterials make them strong candidates for RA treatment.


However, nanomaterials application from laboratory research to clinical practice is difficult and complicated. This article discussed the challenges that nanomaterials may encounter in clinical translation ranging from the complexity of nanomedicine components, the toxicity of new components, the difficulty of quality control, the difficulty of transition from lab process to production, to the limitation of RA model. It is believed that with the continuous innovation and development of technology, nanomaterials may replace a large proportion of traditional medicines in the treatment of rheumatoid arthritis in the future.

The article first summarized in detail the unique factors of RAM and their internal associations, then provided a comprehensive description of the vicious circle of RONs and inflammatory factors in the RA progress. The article also elucidated the comparative advantages of nanomaterials to traditional medication and the method for precise treatment through passive and active RAM targeting. Finally, the article presented the overall challenges and perspective of nanomaterials application in RA treatment.

The joint team also published a review article titled “Reactive oxygen species-based nanomaterials for the treatment of myocardial ischemia-reperfusion injuries” in Bioactive Materials (IF=14.593, Q1), and a review paper titled “Nanotherapies for sepsis by regulating inflammatory signals and reactive oxygen and nitrogen species: New insight for treating COVID-19” in Redox Biol (IF=11.799, Q1).

The Department of Pharmacy of Xiangya Hospital, Central South University has been long devoted to clinically oriented research targeting major national needs in areas of innovative drug development, pharmacological mechanisms, drug preparation and delivery, clinical medication and safety assessment, rational and safe infusion management, and toxicity testing.

 Link to the article: https://www.sciencedirect.com/science/article/pii/S1748013221002838?dgcid=author

Xiangya Hospital Central South University
All Rights Reserved